Exhibit 165







PROFESSIONALS

In This Section

- » Prescription Opioids
- » Laxatives
- » Antiseptics
- » Dietary Supplements

Information About Safe Disposal of Opioids

LEARN MORE ▶

Purdue Products

Purdue and its subsidiaries is a pioneer in medical science with a patient-first approach in developing prescription and non-prescription medications.

We focus on balancing innovative science with clinically effective, compassionate care. Through strategic partnerships with a range of companies, Purdue continues







- Prescription Opioids
- Laxatives
- Antiseptic
- In This Section Dietary St
 - » Prescription Opioids

See the list (

» Laxatives

Please revie

» Antiseptics

ription Products.

Please revie

» Dietary Supplements

3 Returns Goods

Policy for No

Purc

Information About Safe **Disposal of Opioids**

na

ollaborations.

LEARN MORE

How to Report an Adverse Event

To report an adverse event related to a Purdue product, call 888-726-7535 and select option 2.



Prescription Opioids

Purdue developed extended-release formulations containing opioid agonists such as oxycodone, morphine, buprenorphine, and hydrocodone. For many years, Purdue has been an industry leader in the fight against opioid abuse and diversion.







In This Section

- » Prescription Opioids
- » Laxatives
- » Antiseptics
- » Dietary Supplements

tem

Bu

Information About Safe Disposal of Opioids

sdermal

• F

• N

LEARN MORE >

REMS

• Ir

IMPORTANT SAFETY INFORMATION

WARNING: ADDICTION, ABUSE and MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS

Addiction, Abuse, and Misuse

BUTRANS[®] exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing BUTRANS, and monitor all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1) and Overdosage (10)].





required a Risk Evaluation and Mitigation Strategy (REMS) for these products. (5.2)

In This Section

<u>Life-Thr</u>

» Prescription Opioids

ay occur with

Serious, use of B

» Laxatives scially during

» Antiseptics

e or abuse of

BUTRAN

» Dietary Supplements

Jprenorphine

extracted from the transdermal system will result in the uncontrolled delivery '' 'erdose and

death [s

Information About Safe Disposal of Opioids

LEARN MORE

<u>Acciden</u>

Acciden _____

cially in children,

ngs and

can resu Precauti

Neonatal Opioid Withdrawal Syndrome

Prolonged use of BUTRANS during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see Warnings and Precautions (5.4)].

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death [see *Warnings and Precautions (5.5), Drug Interactions (7)*].





- · Limit dosages and durations to the minimum required.
- Follow patients for signs and symptoms of respiratory depression and sedati

In This Section

- » Prescription Opioids
- » Laxatives
- » Antiseptics

Read fu

» Dietary Supplements

Information About Safe Disposal of Opioids



Hysingla[™] ER (hydrocodone bitartrate) extended-release tablets CII

- Full Prescribing Information
- Medication Guide
- Opioid Analgesic REMS
- Safety Data Sheet
- HysinglaER.com

IMPORTANT SAFETY INFORMATION

WARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID







Addiction, Abuse, and Misuse

HYSING In This Section

» Prescription Opioids

all patie

» Laxatives» Antiseptics

conditio

Assess

» Dietary Supplements

cs of opioid

and death.

ER, and monitor

ors and

Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)

To ensure that the banefite of anield analossies outwaish the risks of

addictio required

products

Information About Safe Disposal of Opioids

ration (FDA) has

for these

<u>Life-Thr</u>

LEARN MORE ▶

Serious, ay occur with

use of HYSINGLA ER. Monitor for respiratory depression, especially during initiation of HYSINGLA ER or following a dose increase. Instruct patients to swallow HYSINGLA ER tablets whole; crushing, chewing, or dissolving HYSINGLA ER tablets can cause rapid release and absorption of a potentially fatal dose of hydrocodone [see Warnings and Precautions (5.3)].

Accidental Ingestion

Accidental ingestion of even one dose of HYSINGLA ER, especially by children, can result in a fatal overdose of hydrocodone [see Warnings and Precautions (5.3)].

Neonatal Opioid Withdrawal Syndrome

Prolonged use of HYSINGLA ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal







Cytochrome P450 3A4 Interaction

The concomitant use of HYSINGLA ER with all cytochrome P450 3A4

inhibitor In This Section

eactions and

concent may cau

» Prescription Opioids tion,

disconti

» Laxatives
) 3A4 inducer

disconti

» Antiseptics

ration. Monitor

may res

» Dietary Supplements

r or inducer [see

Warnings and Precautions (5.5), Drug Interactions (7), and Clinical

Pharmac ' '12 2\1

Risks Fr

Information About Safe Disposal of Opioids

ner CNS

<u>Depress</u>

Concom

system (LEARN MORE ▶

r central nervous

n profound arnings and

sedation

Precautions (5.6), Drug Interactions (7)].

- Reserve concomitant prescribing of HYSINGLA ER and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.
- Limit dosages and durations to the minimum required.
- Follow patients for signs and symptoms of respiratory depression and sedation.

Read full Important Safety Information















In 1955, Purdue introduced the first Senokot®-brand laxative. Today, Avrio Health is a leader in consumer health medications to treat occasional constipation. Learn

more about In This Section

In 2002, Pur IN-1) to trea

softener, wa

- » Prescription Opioids
- » Laxatives
- » Antiseptics
- » Dietary Supplements

v called Colace® 2-

dye-free stool

Ith's Colace® here.

Antise

For more that worldwide a Betadine® ir minor cuts,

Information About Safe Disposal of Opioids

LEARN MORE ▶

I in hospitals

For home use,

vent infection in
's Betadine® here.

Dietary Supplements

SlowMag[™] magnesium supplement with high absorption magnesium chloride plus calcium helps support healthy muscle function.* Learn more about Avrio Health's SlowMag[™] here.

*These statements have not been evaluated by the Food and Drug Administration.

This product is not intended to diagnose, treat, cure, or prevent any disease.

TERMS & CONDITIONS

CONTACT US

PRIVACY POLICY

LOCATION & OPERATIONS

ASK PURDUE MEDICAL

ETHICS & COMPLIANCE







 $\hbox{Purdue, as used in this site, refers to Purdue\ Pharma\ L.P.\ and\ its\ subsidiaries,\ which\ includes\ Avrio}$

Health L.P.,

ıfield BioVentures L.P.,

uring L.P.

In This Section

- » Prescription Opioids
- » Laxatives
- » Antiseptics
- » Dietary Supplements

Information About Safe Disposal of Opioids

LEARN MORE ▶